… frequent with dapagliflozin, regardless of polypharmacy status. These findings further support
the use of dapagliflozin as a safe and effective treatment option for patients with HFmrEF or …

… Second, due to greater associated comorbidity, polypharmacy, and other factors, frail patients
… Therefore, we examined the efficacy and safety of dapagliflozin according to frailty status, …

… the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart …
of dapagliflozin according to frailty status using the Rockwood cumulative deficit approach. …

Purpose of Review We provide a review of considerations when applying principles of optimal
pharmacotherapy to older adults with heart failure (HF), an analysis on the pivotal clinical …

… (GDMT) to treat heart failure (HF), polypharmacy, broadly defined as … Polypharmacy is
important because it is associated with a … Dapagliflozin in patients with heart failure and reduced …

… and clinically important benefits of dapagliflozin in HF, irrespective of gout status. … reactions;
and less polypharmacy, which could improve patient adherence to lifesaving HF therapies. …

… in older patients associated with frailty, polypharmacy, … , patients were randomized to
dapagliflozin 10 mg or placebo once daily. Randomization was stratified by type 2 diabetes status …

… As populations in many countries age rapidly, the number of elderly patients with heart failure
(… because of polypharmacy. The benefit of therapy may also be questioned in the elderly. …

… , dapagliflozin prolonged survival and reduced the risks of CKD progression and hospitalization
for heart failure or cardiovascular … versus placebo on efficacy outcomes by frailty status. …

… of diabetes status. In May 2020, the US Food and Drug Administration (FDA) approved …
-based therapies in HF has the potential to lessen polypharmacy and improve adherence. …